• Molecular NameCefoperazone
  • SynonymCefoperazono [inn-spanish]; Cefoperazonum [inn-latin]
  • Weight645.678
  • Drugbank_IDDB01329
  • ACS_NO62893-19-0
  • Show 3D model
  • LogP (experiment)0.74
  • LogP (predicted, AB/LogP v2.0)-0.37
  • pkaN/A
  • LogD (pH=7, predicted)-4.29
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.95
  • LogSw (predicted, AB/LogsW2.0)6.53
  • Sw (mg/ml) (predicted, ACD/Labs)0.05
  • No.of HBond Donors4
  • No.of HBond Acceptors17
  • No.of Rotatable Bonds9
  • TPSA270.86
  • StatusFDA approved, US withdrawn
  • AdministrationN/A
  • PharmacologyA third generation cephalosporin antibiotic, marketed by Pfizer under the name Cefobid, and also marked by pharco B international under the name of Cefazone. It is one of few cephalosporin antibiotics effective in treating Pseudomonas bacterial infections which are otherwise resistant to these antibiotics.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability10.0
  • Protein binding91.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionHepatic
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A